-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $35

Benzinga·11/10/2026 14:21:03
Jefferies analyst Akash Tewari initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $35.